Interventions and Follow-up
Two 30-person diets, comprising 15 single diets of Kaletra
(lopinavir/ritonavir) + hydroxychloroquine (HCQ) with/without NAC (600
mg TDS) and atazanavir/ritonavir + HCQ with/without NAC (600 mg TDS),
were administered in the study. Sixty patients completed the study. (15
patient: Kaletra + HCQ / 15 patient: Kaletra + HCQ + NAC / 15 patient:
atazanavir/ritonavir + HCQ / 15 patient: atazanavir/ritonavir + HCQ +
NAC) The control and intervention groups received the national protocol
treatment, and NAC was added to the treatment of the intervention group.
Since the eligible patients had no contraindications for NAC, the
protocol was 600 mg orally every 8 hours for 14 days.